it is also reporting encouraging results on a diabetes drug. they had a pretty good run over the last 12 months, up 29%. joining us live from the jpmorgan health care conference is eli lilly chairman and ceo, dr. john lechleiter. doctor, thank you for coming on the show. >> my pleasure. good morning. >> okay. first i've got to ask, you're a great american company. and you have done so many things right. yet the emphasis for your company has been, don't worry, we talked about a lot of cliffs on cnbc, don't worry about the patent cliff, the cavalry is coming in diabetes and cancer. why not accept the fact that you had a bad patent cliff and tell people not to worry. in 2014, 2015, you'll be in good shape. >> i think that message is starting to come through. first of all, we've been very successful in driving growth in those areas that are sort of countercyclical through this period. our health business, japan would be another example, and china, among our emerging markets. we're also advancing our pipeline. we have 13 molecules in late stage deve